<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04895410</url>
  </required_header>
  <id_info>
    <org_study_id>M20-917</org_study_id>
    <secondary_id>2021-001067-24</secondary_id>
    <nct_id>NCT04895410</nct_id>
  </id_info>
  <brief_title>Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab (TJ011133) With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma</brief_title>
  <official_title>A Phase 1b, Dose Escalation and Expansion Study of Lemzoparlimab (TJ011133) With or Without Dexamethasone and in Combination With Anti-Myeloma Regimens for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple myeloma (MM) accounts for more than 10% of all blood cancers and 1% of all cancers.&#xD;
      The purpose of this study is to assess how safe lemzoparlimab (TJ01133) is and how&#xD;
      lemzoparlimab (TJ01133) moves through the body of adult participants with MM when given with&#xD;
      or without dexamethasone, and in combination with other anti-myeloma regimens. Adverse events&#xD;
      and change in disease activity will be assessed.&#xD;
&#xD;
      Lemzoparlimab (TJ01133) is an investigational drug being developed for the treatment of&#xD;
      relapsed/refractory (R/R) MM. Study doctors put the participants in groups called treatment&#xD;
      arms. Two different dose levels of lemzoparlimab (TJ011133) will be explored. Each treatment&#xD;
      arm receives a different treatment combination depending on stage of the study and&#xD;
      eligibility. This study will include a dose escalation phase to determine the best dose of&#xD;
      lemzoparlimab (TJ011133), followed by a dose expansion phase to confirm the dose.&#xD;
      Approximately 163 adult participants with R/R MM will be enrolled in the study in&#xD;
      approximately 60 sites worldwide.&#xD;
&#xD;
      In the Dose Escalation arms, participants will receive intravenous (IV) lemzoparlimab&#xD;
      (TJ011133) with or without dexamethasone (oral/IV) in combination with pomalidomide (oral) or&#xD;
      carfilzomib (IV) or subcutaneous (SC) daratumumab in 28-day cycles. In the Dose Expansion&#xD;
      arms, participants will receive lemzoparlimab (TJ011133) (IV) alone or with dexamethasone&#xD;
      (oral/IV) in combination with pomalidomide (oral) or carfilzomib (IV) or daratumumab (SC) in&#xD;
      28-day cycles.&#xD;
&#xD;
      There may be higher treatment burden for participants in this trial compared to their&#xD;
      standard of care. Participants will attend regular visits during the study at an approved&#xD;
      institution (hospital or clinic). The effect of the treatment will be frequently checked by&#xD;
      medical assessments, blood tests and side effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2021</start_date>
  <completion_date type="Anticipated">August 10, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 10, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLTs) of Lemzoparlimab (TJ011133) With or Without Dexamethasone and in Combination With Anti-myeloma Regimens in Participants With Relapsed/Refractory (R/R) Multiple Myeloma (MM)</measure>
    <time_frame>Up to 28 days after study drug administration</time_frame>
    <description>DLT events as described in the protocol will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Best Overall Response of Documented Partial Response (PR) or Better</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Best overall response is defined as achieving documented PR or better at two consecutive disease assessments during the study, according to International Myeloma Working Group (IMWG) 2016 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>PFS is defined as the time from the first dose of study drug to the first documented progressive disease (PD) or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>DOR is defined as the time from first documented response (PR or better) to the first documented PD or death due to MM, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>TTP is defined as the time from the first dose of study drug to the first documented PD or death due to MM, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Dose Escalation: Lemzoparlimab (TJ01133)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lemzoparlimab (TJ01133) in 28 day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation: Lemzoparlimab + Pomalidomide + Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lemzoparlimab (TJ01133) + pomalidomide + dexamethasone in 28 day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation: Lemzoparlimab + Carfilzomib + Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lemzoparlimab (TJ01133) + carfilzomib + dexamethasone in 28 day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation: Lemzoparlimab + Daratumumab + Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lemzoparlimab (TJ01133) + daratumumab + dexamethasone in 28 day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: Lemzoparlimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lemzoparlimab (TJ01133) at recommended dose determined in Dose Escalation portion in 28 day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: Lemzoparlimab + Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lemzoparlimab (TJ01133) at recommended dose determined in Dose Escalation portion + dexamethasone in 28 day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: Lemzoparlimab + Pomalidomide + Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lemzoparlimab (TJ01133) at recommended dose determined in Dose Escalation portion + pomalidomide + dexamethasone in 28 day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: Lemzoparlimab + Carfilzomib + Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lemzoparlimab (TJ01133) at recommended dose determined in Dose Escalation portion + carfilzomib + dexamethasone in 28 day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: Lemzoparlimab + Daratamumab + Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lemzoparlimab (TJ01133) at recommended dose determined in Dose Escalation portion + daratamumab + dexamethasone in 28 day cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lemzoparlimab</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>Dose Escalation: Lemzoparlimab (TJ01133)</arm_group_label>
    <arm_group_label>Dose Escalation: Lemzoparlimab + Carfilzomib + Dexamethasone</arm_group_label>
    <arm_group_label>Dose Escalation: Lemzoparlimab + Daratumumab + Dexamethasone</arm_group_label>
    <arm_group_label>Dose Escalation: Lemzoparlimab + Pomalidomide + Dexamethasone</arm_group_label>
    <arm_group_label>Dose Expansion: Lemzoparlimab</arm_group_label>
    <arm_group_label>Dose Expansion: Lemzoparlimab + Carfilzomib + Dexamethasone</arm_group_label>
    <arm_group_label>Dose Expansion: Lemzoparlimab + Daratamumab + Dexamethasone</arm_group_label>
    <arm_group_label>Dose Expansion: Lemzoparlimab + Dexamethasone</arm_group_label>
    <arm_group_label>Dose Expansion: Lemzoparlimab + Pomalidomide + Dexamethasone</arm_group_label>
    <other_name>TJ011133</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Oral tablet or IV infusion/injection</description>
    <arm_group_label>Dose Escalation: Lemzoparlimab + Carfilzomib + Dexamethasone</arm_group_label>
    <arm_group_label>Dose Escalation: Lemzoparlimab + Daratumumab + Dexamethasone</arm_group_label>
    <arm_group_label>Dose Escalation: Lemzoparlimab + Pomalidomide + Dexamethasone</arm_group_label>
    <arm_group_label>Dose Expansion: Lemzoparlimab + Carfilzomib + Dexamethasone</arm_group_label>
    <arm_group_label>Dose Expansion: Lemzoparlimab + Daratamumab + Dexamethasone</arm_group_label>
    <arm_group_label>Dose Expansion: Lemzoparlimab + Dexamethasone</arm_group_label>
    <arm_group_label>Dose Expansion: Lemzoparlimab + Pomalidomide + Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Dose Escalation: Lemzoparlimab + Carfilzomib + Dexamethasone</arm_group_label>
    <arm_group_label>Dose Expansion: Lemzoparlimab + Carfilzomib + Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Dose Escalation: Lemzoparlimab + Pomalidomide + Dexamethasone</arm_group_label>
    <arm_group_label>Dose Expansion: Lemzoparlimab + Pomalidomide + Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Subcutaneous (SC) injection</description>
    <arm_group_label>Dose Escalation: Lemzoparlimab + Daratumumab + Dexamethasone</arm_group_label>
    <arm_group_label>Dose Expansion: Lemzoparlimab + Daratamumab + Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of relapsed/refractory (R/R) multiple myeloma (MM) with documented evidence&#xD;
             of progression during or after the participant's last treatment regimen based on the&#xD;
             investigator's determination of the International Myeloma Working Group (IMWG)&#xD;
             criteria.&#xD;
&#xD;
               -  Relapsed defined as previously treated myeloma that progresses and requires&#xD;
                  initiation of salvage therapy, but does not meet criteria for refractory myeloma.&#xD;
&#xD;
               -  Refractory defined as disease that is nonresponsive (failure to achieve minimal&#xD;
                  response or development of progressive disease) while on primary or salvage&#xD;
                  therapy, or progresses within 60 days of last therapy.&#xD;
&#xD;
          -  Measurable disease within 28 days prior to enrollment.&#xD;
&#xD;
          -  Arm A - Lemzoparlimab (TJ011133) with or without Dexamethasone&#xD;
&#xD;
               -  For Both Escalation and Expansion Phase, participant must have refractory to 3&#xD;
                  prior lines of treatment including standard of care (SOC).&#xD;
&#xD;
          -  Arm B - Lemzoparlimab (TJ011133) + Pomalidomide-Dexamethasone&#xD;
&#xD;
               -  For Escalation Phase - Participant must have received at least 2 prior lines of&#xD;
                  therapy, including lenalidomide and a Proteasome inhibitor (PI).&#xD;
&#xD;
               -  For Expansion Phase - Participant must have received at least 1 prior line of&#xD;
                  therapy, including lenalidomide and a Proteasome inhibitor (PI).&#xD;
&#xD;
          -  Arm C - Lemzoparlimab (TJ011133) + Carfilzomib-Dexamethasone&#xD;
&#xD;
               -  For Both Escalation and Expansion Phase - Participant must have received at least&#xD;
                  1 prior line of therapy.&#xD;
&#xD;
          -  Arm D - Lemzoparlimab (TJ011133) + Daratumumab-Dexamethasone&#xD;
&#xD;
               -  For Escalation Phase: Participant must have received at least 3 prior lines of&#xD;
                  therapy including a PI and an Immunomodulatory imide drug (IMiD).&#xD;
&#xD;
               -  For Expansion Phase: Participant must have received at least 1 prior line of&#xD;
                  therapy including a PI and an IMiD.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Arm B - Lemzoparlimab (TJ011133) + Pomalidomide-Dexamethasone&#xD;
&#xD;
               -  For Both Escalation and Expansion Phase participant must have had no prior&#xD;
                  treatment with pomalidomide.&#xD;
&#xD;
          -  Arm C - Lemzoparlimab (TJ011133) + Carfilzomib-Dexamethasone&#xD;
&#xD;
               -  For Both Escalation and Expansion Phase - prior treatment with carfilzomib.&#xD;
&#xD;
          -  Arm D - Lemzoparlimab (TJ011133) + Daratumumab-Dexamethasone&#xD;
&#xD;
               -  For Both Escalation and Expansion Phase - prior treatment with daratumumab or&#xD;
                  other anti-CD38 therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona Cancer Center - Tucson /ID# 229696</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale University /ID# 230438</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer /ID# 228817</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136-1002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center /ID# 229939</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Markey Cancer Center /ID# 229506</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-7001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute - St Matthews /ID# 229319</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tulane Cancer Center Clinic /ID# 229832</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital /ID# 229326</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health Systems /ID# 229309</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System /ID# 230341</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey /ID# 230174</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center /ID# 229971</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3729</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Hospital /ID# 229564</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Perelman Center for Advanced Medicine - /ID# 228693</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-5127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 229473</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246-2003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center /ID# 228830</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-7208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Virginia /ID# 229396</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Concord Hospital /ID# 229351</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital /ID# 229343</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital /ID# 229345</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital /ID# 229348</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alfred Health /ID# 229347</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>HCL - Hôpital Lyon Sud /ID# 229834</name>
      <address>
        <city>Pierre Benite CEDEX</city>
        <state>Auvergne-Rhone-Alpes</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes, Hotel Dieu -HME /ID# 228559</name>
      <address>
        <city>Nantes</city>
        <state>Pays-de-la-Loire</state>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Poitier - La milétrie /ID# 229833</name>
      <address>
        <city>Poitiers</city>
        <state>Poitou-Charentes</state>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor /ID# 228562</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Heidelberg /ID# 229145</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus /ID# 230290</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70736</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charite Universitaetsklinikum Berlin - Campus Benjamin Franklin /ID# 230291</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg-Eppendorf (UKE) /ID# 229141</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona /ID# 229143</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar - Technische Universitaet Muenchen /ID# 230007</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center /ID# 229483</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tel-Aviv</state>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center /ID# 229478</name>
      <address>
        <city>Tel Aviv-Yafo</city>
        <state>Tel-Aviv</state>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus /ID# 229485</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center-Hebrew University /ID# 229477</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center /ID# 229480</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center /ID# 229488</name>
      <address>
        <city>Petakh Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago-CHUS /ID# 229356</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruna</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Unversitario Marques de Valdecilla /ID# 229354</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Parc de Salut del Mar /ID# 229371</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau /ID# 229369</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia /ID# 229388</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre /ID# 229355</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust /ID# 228332</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust /ID# 228323</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust /ID# 228328</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust /ID# 228333</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie Hospital /ID# 228330</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lemzoparlimab</keyword>
  <keyword>ABBV-IMAB-TJC4</keyword>
  <keyword>Relapsed or refractory multiple myeloma (R/R MM)</keyword>
  <keyword>Cancer</keyword>
  <keyword>TJ011133</keyword>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

